Payment overview · 2025
General Payments
$90.51
4 reported records · 3 companies
Healthcare provider profile · identity verified
Daniel Robert Doman, DO
Allopathic & Osteopathic Physicians|Family Medicine · TECUMSEH, MI · NPI 1194712471
Verified facts
What the public records show
CMS Open Payments records show Daniel Robert Doman, DO received $90.51 in general payments during 2025 across 4 reported records.
PFIZER INC. accounted for 54.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nurtec Odt, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.72 | 54.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.78 | 26.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.01 | 18.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $90.51 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 248 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
166 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
248 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 829 | 202 |
| Amlodipine Besylate | Amlodipine Besylate | 609 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 480 | 96 |
| Gabapentin | Gabapentin | 467 | 83 |
| Omeprazole | Omeprazole | 440 | 109 |
| Lisinopril | Lisinopril | 412 | 101 |
| Losartan Potassium | Losartan Potassium | 388 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 339 | 84 |
| Glimepiride | Glimepiride | 319 | 74 |
| Metformin Hcl | Metformin Hcl | 305 | 78 |
| Simvastatin | Simvastatin | 260 | 68 |
| Eliquis | Apixaban | 248 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 239 | 33 |
| Alprazolam | Alprazolam | 233 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 214 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 51 |
| Potassium Chloride | Potassium Chloride | 210 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 201 | 54 |
| Trazodone Hcl | Trazodone Hcl | 182 | 40 |
| Furosemide | Furosemide | 175 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 48 |
| Ozempic | Semaglutide | 166 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 33 |
| Jardiance | Empagliflozin | 132 | 31 |
| Meloxicam | Meloxicam | 126 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 124 | 33 |
| Celecoxib | Celecoxib | 120 | 30 |
| Allopurinol | Allopurinol | 117 | 29 |
| Atenolol | Atenolol | 116 | 24 |
| Carvedilol | Carvedilol | 108 | 24 |
| Finasteride | Finasteride | 104 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 26 |
| Alendronate Sodium | Alendronate Sodium | 103 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 20 |
| Prednisone | Prednisone | 94 | 59 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 21 |
| Xarelto | Rivaroxaban | 91 | 11 |
| Clonazepam | Clonazepam | 88 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 23 |
| Warfarin Sodium | Warfarin Sodium | 88 | 15 |
| Sertraline Hcl | Sertraline Hcl | 86 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 26 |
| Bumetanide | Bumetanide | 81 | 18 |
| Mirtazapine | Mirtazapine | 81 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 78 | suppressed |
| Pregabalin | Pregabalin | 76 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 20 |
| Trulicity | Dulaglutide | 73 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 16 |
| Ibuprofen | Ibuprofen | 64 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 14 |
| Spironolactone | Spironolactone | 62 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 13 |
| Nystatin | Nystatin | 57 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 57 | 11 |
| Bupropion Xl | Bupropion Hcl | 56 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 13 |
| Lorazepam | Lorazepam | 53 | 11 |
| Famotidine | Famotidine | 52 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 13 |
| Donepezil Hcl | Donepezil Hcl | 50 | 13 |
| Ezetimibe | Ezetimibe | 48 | 12 |
| Tramadol Hcl | Tramadol Hcl | 48 | 12 |
| Montelukast Sodium | Montelukast Sodium | 47 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Azithromycin | Azithromycin | 41 | 40 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 34 |
| Ondansetron Odt | Ondansetron | 41 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | 12 |
| Cephalexin | Cephalexin | 38 | 25 |
| Meclizine Hcl | Meclizine Hcl | 38 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 17 |
| Mupirocin | Mupirocin | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Klor-Con M10 | Potassium Chloride | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Klayesta | Nystatin | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $90.51 · 4 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, ELIQUIS, NURTEC ODT, PENBRAYA, PREVNAR 20, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error